Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 13/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20040969 | 0.83 | SLC22A12 (0.55) | SLC22A12TAS2R14ARTRPA1 | |
| SCHEMBL8210097 | 0.79 | SLC22A12 (0.54) | SLC22A12TAS2R14ARPGRTRPA1 | |
| SCHEMBL2973749 | 0.79 | AR (0.54) | SLC22A12TAS2R14ARPGRTRPA1 | |
| SCHEMBL20179096 | 0.79 | SLC22A12 (0.54) | SLC22A12TAS2R14ARPGRTRPA1 | |
| SCHEMBL16946784 | 0.79 | AR (0.52) | SLC22A12TAS2R14AR | |
| SCHEMBL17227549 | 0.78 | ALDH1A1 (0.40) | ABCG2 | |
| Hydrochloric Acid SCHEMBL552509 | 0.78 | SLC22A12 (0.52) | SLC22A12TAS2R14ARPGRTRPA1 | |
| SCHEMBL16823496 | 0.78 | TAS2R14 (0.53) | SLC22A12TAS2R14AR | |
| SCHEMBL3054694 | 0.77 | SLC22A12 (0.55) | SLC22A12TAS2R14ARPGR | |
| SCHEMBL14919155 | 0.77 | SLC22A12 (0.55) | SLC22A12TAS2R14ARTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174635-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2017-06-22 | — | — | US | disclosed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174635-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | AR, KLK3, KLK5 | SLC22A12 4607/4885TAS2R14 4696/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.